Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Scrip 100 - Business

External R&D Is Up, But Which Companies Are Reaping The Most Benefit?

Amgen, Novartis and Lilly are projected to increase sales from externally sourced assets in the coming years, according to a Datamonitor Healthcare analysis, while other big pharma – including frequent acquirer Pfizer and smaller-deal-oriented Bristol – are expected to see that ratio decline compared to sales of internally developed drugs.

Business Strategies Deals M & A

Biosimilars: The Unlikely Hero Of Specialty Pharma?

In the patent cliff musical chairs game, the music has stopped and generic companies like Mylan and Teva are looking for the next growth driver. While this seems to be biosimilars, it appears that innovator companies who are used to developing biologics, are already sitting in their seats.

Commercial Biosimilars BioPharmaceutical

Curb Your Enthusiasm: Chinese Pharmas Going Global Hit Speed Bumps

Ambitious and confident Chinese pharmaceutical buyers have begun to enter a new brave world of foreign M&A. However, this scenario can be littered with internal challenges and increasingly external scrutiny, less solid pre-deal asset identification and poor post-deal execution, all of which can damage their barely gained credibility, creating hurdles for future deals.

Deals M & A China


Click to download in PDF